LVTX – lava therapeutics n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) [Yahoo! Finance]
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Form 6-K LAVA Therapeutics NV For: Mar 20
Form 20-F LAVA Therapeutics NV For: Dec 31
Form SC 13D/A LAVA Therapeutics NV Filed by: Novo Holdings A/S
Form SC 13G/A LAVA Therapeutics NV Filed by: Redmile Group, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.